Latest news with #CLARA
Business Wire
4 days ago
- Business
- Business Wire
CLARA Analytics Expands AI Platform to Combat Bad Faith Claims and Social Inflation
SUNNYVALE, Calif.--(BUSINESS WIRE)-- CLARA Analytics ('CLARA'), a leading provider of artificial intelligence (AI) technology for insurance claims optimization, today announced major enhancements to its Claims DocIntel Pro that directly combat the industry's mounting losses from bad faith claims and social inflation. The upgraded platform introduces dynamic medical summarization and advanced legal demand analytics designed to help insurers prevent costly nuclear verdicts while accelerating claims processing. "By combining deep document intelligence with predictive analytics and proactive alerts, we're helping insurers, third-party administrators (TPAs), and self-insured organizations achieve faster time-to-insights and significantly higher ROI." With social inflation driving claim costs up annually, insurers face unprecedented pressure to identify risks early and respond decisively. Claims DocIntel Pro's new capabilities address these challenges head-on by automatically flagging time-sensitive legal demands, analyzing plaintiff attorney behavior patterns, and delivering AI-generated medical summaries that eliminate manual document review. 'CLARA is pushing the boundaries of innovation to deliver unparalleled value to our customers,' said Heather H. Wilson, CEO of CLARA Analytics. 'These new enhancements to Claims DocIntel Pro enable claims professionals to focus on what matters most, providing them with precise, AI-driven insights that enhance efficiency and improve outcomes. The new release goes further than ever in identifying time-sensitive issues and preventing bad faith claims. It also simplifies and accelerates the onboarding process for new employees, getting them to full productivity faster than ever.' Leveraging generative AI, machine learning, and an industry-leading body of contributory data, CLARA's advanced AI platform processes thousands of pages automatically, extracting critical insights such as legal risks, medical complexities, and time-sensitive demands. Claims DocIntel Pro generates dynamic case summaries and organizes records into a searchable, chronological timeline, alerting adjusters to important information that requires their attention. The platform's dynamic medical summarization provides claims adjusters with four precisely tailored AI-generated summaries: comprehensive initial injury information, detailed ongoing medical care, additional care considerations, and prior injuries or comorbidities. Unlike static, outdated summaries, these laser-focused insights eliminate the need for adjusters to craft complex AI chatbot prompts or navigate extensive documents manually. Designed by CLARA's subject matter experts, these intelligent summaries deliver consistent, precise and highly relevant actionable information, enabling adjusters of all experience levels to make informed decisions with unprecedented speed. Built on the platform, Claims DocIntel Pro integrates with the company's complete portfolio of claims management products, offering claims management teams a unified, streamlined experience. This tight integration connects extracted document data to CLARA's contributory database and machine learning models, offering a holistic view of claim severity, litigation risks, and analytics. This approach sets CLARA apart from competitors who offer fragmented solutions, requiring multiple vendors. Designed for adjusters of all experience levels, Claims DocIntel Pro reduces manual workloads, enhances decisions, prevents costly oversights, and improves efficiency. 'CLARA's platform is uniquely positioned to deliver a comprehensive claims life cycle solution,' said Mubbin Rabbani, Chief Product Officer at CLARA Analytics. 'By combining deep document intelligence with predictive analytics and proactive alerts, we're helping insurers, third-party administrators (TPAs), and self-insured organizations achieve faster time-to-insights and significantly higher ROI.' CLARA Analytics will showcase the enhanced Claims DocIntel Pro capabilities at the upcoming Insurtech Insights 2025 conference. CEO Wilson will participate in the panel discussion 'Data-Driven Decisions: Revolutionizing Claims with Analytics and Insights,' scheduled for June 4 at 11:10 a.m. on the Orange Stage at the Javits Center in New York. Conference attendees will have the opportunity to learn more about CLARA's breakthrough AI technology and how it is transforming claims processing to deliver unprecedented value to insurance professionals. About CLARA Analytics CLARA Analytics is the leading AI as a service (AIaaS) provider that improves casualty claims outcomes for insurance carriers, MGAs, reinsurers, and self-insured organizations. The company's platform, applies image recognition, natural language processing, and other AI-based techniques to unlock insights from medical notes, legal demand packages, bills and other documents surrounding a claim. CLARA's predictive insights give claim professionals augmented intelligence that helps them reduce claim costs and optimize outcomes for the carrier, customer and claimant. CLARA's customers include companies from the top 25 global insurance carriers to large third-party administrators and self-insured organizations. Founded in 2017, CLARA Analytics is headquartered in California's Silicon Valley. For more information, visit and follow the company on LinkedIn and @CLARAAnalytics. All brand names and solution names are trademarks or registered trademarks of their respective companies. Tags: CLARA Analytics, Claims DocIntel Pro, insurtech, claims, claims optimization, claims adjusters, claims managers, artificial intelligence, AI, generative AI, GenAI, machine learning, claims management, bad faith claims, social inflation, nuclear verdicts, predictive analytics, workers compensation, commercial insurance, general liability
Business Wire
07-05-2025
- Business
- Business Wire
CLARA Analytics Unveils AI-Driven Subrogation Detection for Insurance Claims
SUNNYVALE, Calif.--(BUSINESS WIRE)-- CLARA Analytics ('CLARA'), a leading provider of artificial intelligence (AI) technology for insurance claims optimization, today announced game-changing subrogation detection capabilities that promise to help insurers identify millions in previously missed recovery opportunities. The enhancements to CLARA's flagship CLARA Triage product automatically identify potential subrogation and risk transfer opportunities, providing narrative assessments and numeric scores that help claims adjusters to focus on cases that offer the greatest potential. "The market has a significant gap in regard to subrogation opportunity identification. Our mission is to transform the way claims management teams work with their subrogation partners to deliver transformative financial results." With the National Association of Insurance Commissioners (NAIC) estimating $15 billion in annual missed subrogation opportunities due to manual workflows and documentation issues, CLARA's new technology directly addresses one of the industry's most significant financial challenges. Existing users of CLARA Triage have improved their combined ratios by 2%-5% after a year of claims development. 'CLARA's core values include constant innovation and an obsessive focus on our customers' needs,' said Heather H. Wilson, CEO at CLARA Analytics. 'The market has a significant gap in regard to subrogation opportunity identification. Our mission is to transform the way claims management teams work with their subrogation partners to deliver transformative financial results. Our new subrogation detection capabilities are a major step forward in that journey.' CLARA Triage helps insurance companies, third-party administrators (TPAs), and risk managers at self-insured enterprises to identify and prioritize high-risk claims continuously from first notice of loss until final settlement. It leverages predictive and generative AI technology to assess the severity and complexity of each claim, enabling adjusters to make fully informed decisions and improve overall outcomes. CLARA's large contributory database draws from the experience of multiple carriers, providing a foundation for deep contextual understanding of medical and legal risk. CLARA's new subrogation detection capabilities are a major advancement for the Triage product, leveraging the company's comprehensive insurance claims data with best-in-class GenAI and machine learning models to identify potential recoverable opportunities, score those opportunities based on likely financial returns, and offer AI explainability narratives of potential subrogation scenarios. Triage ingests new claims data as soon as it becomes available, updating scores and alerting claims managers when a key threshold is met. CLARA periodically delivers ROI reports to each of its clients with high adoption of their platform, demonstrating a payback of 500% in most cases, with some achieving even much higher gains. With the release of the new subrogation and risk transfer features in CLARA Triage, the company aims to further increase the value it provides to its customers. 'CLARA's company culture is all about reaching higher, always looking for ways to add more value for our customers,' Wilson continued. 'With these new subrogation and risk transfer detection capabilities, we can help insurers achieve even higher ROI.' About CLARA Analytics CLARA Analytics is the leading AI as a service (AIaaS) provider that improves casualty claims outcomes for insurance carriers, MGAs, reinsurers, and self-insured organizations. The company's platform, applies image recognition, natural language processing, and other AI-based techniques to unlock insights from medical notes, legal demand packages, bills, and other documents surrounding a claim. CLARA's predictive insights give claim professionals augmented intelligence that helps them reduce claim costs and optimize outcomes for the carrier, customer and claimant. CLARA's customers include companies from the top 25 global insurance carriers to large third-party administrators and self-insured organizations. Founded in 2017, CLARA Analytics is headquartered in California's Silicon Valley. For more information, visit and follow the company on LinkedIn and @CLARAAnalytics. All brand names and solution names are trademarks or registered trademarks of their respective companies. Tags: CLARA Analytics, CLARA Triage, subrogation, risk transfer, claims optimization, claims adjusters, claims managers, insurtech, claims, claims management, artificial intelligence, AI, generative AI, GenAI, machine learning, workers compensation, workers comp, predictive analytics, commercial insurance, general liability
Yahoo
18-03-2025
- Business
- Yahoo
Aurion Biotech Named to Fast Company's Annual List of the World's Most Innovative Companies of 2025
Ophthalmology Cell Therapy Innovator Included with Other Leading Companies SEATTLE & CAMBRIDGE, Mass & TOKYO, March 18, 2025--(BUSINESS WIRE)--Aurion Biotech, Inc. (Aurion Biotech), whose mission is to restore vision to millions of patients with life-changing regenerative therapies, today announced that the Company is proud to have been named to Fast Company's prestigious list of the World's Most Innovative Companies of 2025. This year's list shines a spotlight on businesses that are shaping industry and culture through their innovations to set new standards and achieve remarkable milestones in all sectors of the economy. Alongside the World's 50 Most Innovative Companies, Fast Company recognizes 609 organizations across 58 sectors and regions. Aurion Biotech was named Number 4 in the Medicines, Therapeutics, and Pharmaceuticals category. "We are delighted to have earned this recognition," said Greg Kunst, CEO of Aurion Biotech. "Aurion's success is a result of the passion, dedication, focus on patients and inspiring contributions of our employees and our physicians." Aurion Biotech has had a busy, productive 18 months. Key achievements included: Enrolled and successfully dosed 97 subjects in its North American Phase 1/2 CLARA trial Sought and received Breakthrough Therapy Designation and Regenerative Medicines Advanced Therapy designation from the U.S. Food and Drug Administration Successfully dosed 25 subjects in the Company's Apaneca clinical trial, to evaluate the safety and efficacy of a cryo-preserved formulation of its drug product candidate Fast Company's World's Most Innovative Companies hallmark franchise is one of its most anticipated editorial efforts of the year. To determine honorees, Fast Company's editors and writers review companies driving progress around the world and across industries, evaluating thousands of submissions through a competitive application process. The result is a globe-spanning guide to innovation today, from early-stage startups to some of the most valuable companies in the world. "Our list of the Most Innovative Companies offers both a comprehensive look at innovation today and a playbook for the future," said Fast Company editor-in-chief Brendan Vaughan. "This year, we recognize companies that are harnessing AI in deep and meaningful ways, brands that are turning customers into superfans by overdelivering for them, and challengers that are introducing bold ideas and vital competition to their industries. At a time when the world is rapidly shifting, these companies are charting the way forward." The full list of Fast Company's Most Innovative Companies honorees can now be found at It will also be available on newsstands beginning March 25. Fast Company will host the Most Innovative Companies Summit and Gala for honorees on June 5. The summit features a day of inspiring content, followed by a creative black-tie gala including networking, a seated dinner, and an honoree presentation. About Aurion Biotech, Inc. Aurion Biotech's mission is to restore vision to millions of patients with life-changing regenerative therapies. It received the prestigious Prix Galien award for best start-up in biotech in 2022. Aurion Biotech is advancing AURN001, an investigational single administration, allogeneic cell therapy to treat corneal edema secondary to corneal endothelial dysfunction. Aurion Biotech developed and has launched the first commercially available corneal endothelial cell therapy in Japan. To learn more, visit ABOUT FAST COMPANY Fast Company is the only media brand fully dedicated to the vital intersection of business, innovation, and design, engaging the most influential leaders, companies, and thinkers on the future of business. Headquartered in New York City, Fast Company is published by Mansueto Ventures LLC, along with fellow business publication Inc. For more information, please visit View source version on Contacts Media Contacts: Judith McGarry (corporate communications) Michele Gray (ophthalmology media) 917-449-9250michele@ Beth Keshishian (biotech & business media) 917-912-7195beth@ Sign in to access your portfolio
Associated Press
18-03-2025
- Business
- Associated Press
Aurion Biotech Named to Fast Company's Annual List of the World's Most Innovative Companies of 2025
SEATTLE & CAMBRIDGE, Mass & TOKYO--(BUSINESS WIRE)--Mar 18, 2025-- Aurion Biotech, Inc. (Aurion Biotech), whose mission is to restore vision to millions of patients with life-changing regenerative therapies, today announced that the Company is proud to have been named to Fast Company 's prestigious list of the World's Most Innovative Companies of 2025. This year's list shines a spotlight on businesses that are shaping industry and culture through their innovations to set new standards and achieve remarkable milestones in all sectors of the economy. Alongside the World's 50 Most Innovative Companies, Fast Company recognizes 609 organizations across 58 sectors and regions. Aurion Biotech was named Number 4 in the Medicines, Therapeutics, and Pharmaceuticals category. 'We are delighted to have earned this recognition,' said Greg Kunst, CEO of Aurion Biotech. 'Aurion's success is a result of the passion, dedication, focus on patients and inspiring contributions of our employees and our physicians.' Aurion Biotech has had a busy, productive 18 months. Key achievements included: Enrolled and successfully dosed 97 subjects in its North American Phase 1/2 CLARA trial Sought and received Breakthrough Therapy Designation and Regenerative Medicines Advanced Therapy designation from the U.S. Food and Drug Administration Successfully dosed 25 subjects in the Company's Apaneca clinical trial, to evaluate the safety and efficacy of a cryo-preserved formulation of its drug product candidate Fast Company's World's Most Innovative Companies hallmark franchise is one of its most anticipated editorial efforts of the year. To determine honorees, Fast Company' s editors and writers review companies driving progress around the world and across industries, evaluating thousands of submissions through a competitive application process. The result is a globe-spanning guide to innovation today, from early-stage startups to some of the most valuable companies in the world. 'Our list of the Most Innovative Companies offers both a comprehensive look at innovation today and a playbook for the future,' said Fast Company editor-in-chief Brendan Vaughan. 'This year, we recognize companies that are harnessing AI in deep and meaningful ways, brands that are turning customers into superfans by overdelivering for them, and challengers that are introducing bold ideas and vital competition to their industries. At a time when the world is rapidly shifting, these companies are charting the way forward.' The full list of Fast Company's Most Innovative Companies honorees can now be found at It will also be available on newsstands beginning March 25. Fast Company will host the Most Innovative Companies Summit and Gala for honorees on June 5. The summit features a day of inspiring content, followed by a creative black-tie gala including networking, a seated dinner, and an honoree presentation. About Aurion Biotech, Inc. Aurion Biotech's mission is to restore vision to millions of patients with life-changing regenerative therapies. It received the prestigious Prix Galien award for best start-up in biotech in 2022. Aurion Biotech is advancing AURN001, an investigational single administration, allogeneic cell therapy to treat corneal edema secondary to corneal endothelial dysfunction. Aurion Biotech developed and has launched the first commercially available corneal endothelial cell therapy in Japan. To learn more, visit ABOUT FAST COMPANY (corporate communications) 415-971-2900 [email protected] Gray (ophthalmology media) 917-449-9250 [email protected] Keshishian (biotech & business media) 917-912-7195 [email protected] INDUSTRY KEYWORD: BIOTECHNOLOGY FDA HEALTH PHARMACEUTICAL OPTICAL SOURCE: Aurion Biotech, Inc. Copyright Business Wire 2025. PUB: 03/18/2025 09:21 AM/DISC: 03/18/2025 09:22 AM
Associated Press
10-02-2025
- Business
- Associated Press
Aurion Biotech Appoints Donald Munoz as Chief Financial Officer
SEATTLE & CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)--Feb 10, 2025-- Aurion Biotech, Inc. (Aurion), whose mission is to restore vision to millions of patients with life-changing regenerative therapies, announced today that Donald Munoz is joining the Company as chief financial officer (CFO), reporting to Greg Kunst, chief executive officer (CEO). 'We are delighted to welcome Don to our executive team,' said Greg Kunst, Aurion's CEO. 'Don's track record of strategic and operational financial leadership, coupled with his extensive experience as a healthcare investment banker, make him an ideal addition to Aurion.' 'I'm thrilled to join Aurion as CFO,' said Don Munoz. 'I believe that Aurion's lead product candidate, AURN001, has significant potential to treat corneal endothelial disease, which can lead to blindness. I look forward to working with the Aurion team to pursue bringing this cell therapy to patients in need.' Donald Munoz has over 30 years of health care experience as a chief financial officer and an investment banker. Prior to joining Aurion, Don spent more than nine years as chief financial officer of NuCana plc (NASDAQ: NCNA) (NuCana), a publicly traded biotechnology company developing oncology therapeutics. At NuCana, Don oversaw financial management, investor relations, Securities and Exchange Commission reporting, audit, tax and financial planning and analysis. Don also led NuCana's $114 million Nasdaq initial public offering and $80 million follow-on offering. Before NuCana, Don was the chief financial officer of NOXXON Pharma N.V., a venture-backed biotechnology company. Previously, Don spent 20 years as a healthcare investment banker leading the medical technology franchises for Cowen & Company, LLC, Leerink Partners LLC and Deutsche Bank AG, which he joined through its acquisition of Alex. Brown & Sons. Don has completed more than 100 financing and strategic advisory transactions throughout his career. Don holds an M.B.A. from Columbia Business School and a B.A. from Dartmouth College. Don's appointment follows Aurion's announcement of positive six-month top-line data from its CLARA Phase 1/2 clinical trial in the United States and Canada in December 2024. More information about Aurion's recent progress can be found on its website: Aurion's mission is to restore vision to millions of patients with life-changing regenerative therapies. It received the prestigious Prix Galien award for best start-up in biotech in 2022. Aurion is advancing AURN001, an investigational, single-administration, allogeneic cell therapy to treat corneal edema secondary to corneal endothelial dysfunction. Aurion developed and has launched the first commercially available corneal endothelial cell therapy in Japan. To learn more, visit . (Corporate Communications) 415-971-2900 [email protected] Gray (Ophthalmology Media) 917-449-9250 [email protected] Keshishian (Biotech & Business Media) 917-912-7195 [email protected] KEYWORD: NORTH AMERICA UNITED STATES ASIA PACIFIC JAPAN CANADA WASHINGTON MASSACHUSETTS INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL OPTICAL HEALTH SOURCE: Aurion Biotech, Inc. Copyright Business Wire 2025. PUB: 02/10/2025 07:00 AM/DISC: 02/10/2025 07:00 AM
